Asset sale Announced
Harrow acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg
US$30m consideration
Announced 6 Aug 2026
Advisers
TYRVAYA (varenicline solution) nasal spray 0.03 mg
Target
- Legal adviser
Harrow
Acquirer
Not disclosed
- Target
- TYRVAYA (varenicline solution) nasal spray 0.03 mg
- Acquirer
- Harrow
- Seller
- Viatris
- Target based in
- United States (unverified)
- Buyer based in
- United States
- Seller based in
- United States
- Sector
- Pharma
- Tags
- Pharma, Ophthalmology
In the league tables
Similar deals
- Tarsus Pharmaceuticals acquisition of iRenix Medical Jul 2026 · US$75m · Ophthalmology
- Biogen acquisition of Apellis Pharmaceuticals Mar 2026 · US$5.6bn · Biotech
- Cosette Pharmaceuticals acquisition of Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) Apr 2026 · US$35m · Pharma
- Subsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog Apr 2026 · US$35m · Pharma
- TELI Pharmaceuticals and Telomir Pharmaceuticals merger US$47.1m · Biotech
Sources
- 11 Aug 2026 Viatris’s Sale of TYRVAYA to Harrow cravath.com
